Khondrion BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.khondrion.com
Clinical Trials
7
Active:1
Completed:4
Trial Phases
3 Phases
Phase 1:2
Phase 2:4
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 1
2 (28.6%)Phase 3
1 (14.3%)KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Phase 3
Not yet recruiting
- Conditions
- Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 150
- Registration Number
- NCT06451757
The KHENERGYC Study
Phase 2
Suspended
- Conditions
- Mitochondrial DiseasesMitochondrial DNA tRNALeu(UUR) m.3243A<G MutationMELASSubacute Necrotizing Encephalomyelopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 24
- Registration Number
- NCT04846036
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
The KHENEREXT Study
Phase 2
Completed
- Conditions
- Maternally Inherited Diabetes and Deafness (MIDD)Mitochondrial DiseasesMitochondrial DNA tRNALeu(UUR) m.3243A<G MutationChronic Progressive External Ophthalmoplegia (CPEO)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
- Interventions
- Drug: Oral administration of 100 mg KH176 twice daily
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 11
- Registration Number
- NCT04604548
- Locations
- 🇩🇰
Rigshospitalet, University of Copenhagen, Kopenhagen, Denmark
🇩🇪Klinikum der Universität München Friedrich-Baur-Institut, München, Germany
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
The KHENERGYZE Study
Phase 2
Completed
- Conditions
- Mitochondrial MyopathiesMitochondrial EncephalomyopathiesMitochondrial DiseasesMELAS SyndromeMIDD
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 27
- Registration Number
- NCT04165239
- Locations
- 🇩🇰
Rigshospitalet, University of Copenhagen, Kopenhagen, Denmark
🇩🇪Friedrich-Baur Institut, München, Bayern, Germany
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
The KHENERGY Study
Phase 2
Completed
- Conditions
- Mitochondrial EncephalomyopathiesMIDDMitochondrial MyopathiesMitochondrial DiseasesMELAS
- Interventions
- Drug: placebo
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Khondrion BV
- Target Recruit Count
- 20
- Registration Number
- NCT02909400
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
- Prev
- 1
- 2
- Next
News
No news found